|Prolor Reports Positive Preclinical Results for Hemophilia Drug Candidate|
|By Staff and Wire Reports|
|Tuesday, 14 February 2012 10:03|
The "in vivo recovery" standard is a pharmacokinetic parameter used by researchers that compares actual clotting activity post-dosing to anticipated clotting activity.
The new study showed that compared to commercially available Factor VIIa, hemophilic mice receiving PROLOR's Factor VIIa-CTP demonstrated:
"The results of our second Factor VIIa-CTP preclinical study are consistent with the results we obtained from the previous study, and we believe they are very promising," noted Shai Novik, President of PROLOR. "With these positive results, we now have what we believe could be a highly competitive coagulation factor that could potentially become a leader in the hemophilia market."
As pointed out by the company's management, there is great need among hemophilia patients and their physicians for new therapies that will provide prolonged protection from bleeding. "The encouraging results seen in our preclinical hemophilia studies suggest that Factor VIIa-CTP may be able to offer an improved therapeutic option for hemophiliacs by reducing the frequency of injections, controlling bleeding more effectively and significantly improving their quality of life," said Dr. Abraham Havron, CEO of PROLOR.
Despite the very positive price action since we began to talk about the stock in late December, we continue to believe that Prolor is a winner and that they are poised to make great strides in the months and years shead. We anticipate that they will meet moree milestones and generate more positive news as we move ahead in 2012.